tiprankstipranks
Silence Therapeutics (SLN)
NASDAQ:SLN
US Market
SLN
Silence Therapeutics
RESEARCH TOOLSreports
Want to see SLN full AI Analyst Report?

Silence Therapeutics (SLN) Ratios

355 Followers

Silence Therapeutics Ratios

SLN's free cash flow for Q1 2026 was £0.72. For the 2026 fiscal year, SLN's free cash flow was decreased by £ and operating cash flow was £-35.65. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 9.83 8.72 11.14 4.62 4.41
Quick Ratio
 9.83 8.72 11.14 4.62 4.41
Cash Ratio
 0.54 0.83 7.21 3.08 2.50
Solvency Ratio
 -1.13 -1.27 -0.65 -0.44 -0.58
Operating Cash Flow Ratio
 -6.27 -4.57 -4.02 -1.76 -2.60
Short-Term Operating Cash Flow Coverage
 -705.00 -699.67 0.00 -172.59 0.00
Net Current Asset Value
£ 37.13M£ 49.52M£ 118.75M£ 5.70M£ 11.26M
Leverage Ratios
Debt-to-Assets Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Debt-to-Equity Ratio
 <0.01 <0.01 <0.01 0.02 0.02
Debt-to-Capital Ratio
 <0.01 <0.01 <0.01 0.02 0.02
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 2.33 2.11 1.51 5.43 4.87
Debt Service Coverage Ratio
 -758.77 -1.00K 0.00 -163.11 -1.30K
Interest Coverage Ratio
 0.00 0.00 0.00 -1.46K -1.30K
Debt to Market Cap
 <0.01 <0.01 0.00 <0.01 0.00
Interest Debt Per Share
 <0.01 <0.01 <0.01 0.03 0.05
Net Debt to EBITDA
 0.08 0.12 2.47 1.37 0.90
Profitability Margins
Gross Profit Margin
66.86%61.54%72.70%59.34%37.83%
EBIT Margin
-8478.88%-16055.99%-114.62%-198.13%-281.87%
EBITDA Margin
-8416.51%-15956.71%-113.25%-196.17%-279.12%
Operating Profit Margin
-9267.51%-16055.99%-146.38%-195.48%-281.87%
Pretax Profit Margin
-8947.11%-15849.91%-102.79%-198.27%-229.26%
Net Profit Margin
-8948.43%-15851.88%-104.74%-170.51%-232.44%
Continuous Operations Profit Margin
-8948.43%-15851.88%-104.74%-170.51%-232.44%
Net Income Per EBT
100.01%100.01%101.90%86.00%101.39%
EBT Per EBIT
96.54%98.72%70.22%101.42%81.33%
Return on Assets (ROA)
-65.16%-67.42%-22.36%-36.22%-46.82%
Return on Equity (ROE)
-107.19%-142.23%-33.81%-196.73%-228.04%
Return on Capital Employed (ROCE)
-74.23%-76.17%-34.08%-51.08%-71.34%
Return on Invested Capital (ROIC)
-74.16%-76.11%-34.06%-43.83%-70.97%
Return on Tangible Assets
-71.77%-73.52%-23.48%-39.66%-50.75%
Earnings Yield
-25.45%-30.86%-42.72%-25.62%-37.20%
Efficiency Ratios
Receivables Turnover
 0.04 0.02 1.61 1.06 23.67
Payables Turnover
 0.03 0.05 3.19 3.08 4.23
Inventory Turnover
 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 0.55 0.32 21.90 10.99 9.84
Asset Turnover
 <0.01 <0.01 0.21 0.21 0.20
Working Capital Turnover Ratio
 <0.01 <0.01 0.34 0.33 0.30
Cash Conversion Cycle
 -3.95K 8.59K 112.78 226.46 -70.95
Days of Sales Outstanding
 9.67K 16.07K 227.04 344.89 15.42
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 13.62K 7.49K 114.26 118.44 86.38
Operating Cycle
 9.67K 16.07K 227.04 344.89 15.42
Cash Flow Ratios
Operating Cash Flow Per Share
 -1.39 -1.32 -4.39 -3.18 -5.32
Free Cash Flow Per Share
 -1.39 -1.32 -4.40 -3.19 -5.37
CapEx Per Share
 <0.01 <0.01 0.01 <0.01 0.05
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.00 1.01
Dividend Paid and CapEx Coverage Ratio
 -618.54 -1.13K -320.57 -874.44 -104.67
Capital Expenditure Coverage Ratio
 -618.54 -1.13K -320.57 -874.44 -104.67
Operating Cash Flow Coverage Ratio
 -482.10 -389.19 -578.12 -113.73 -127.90
Operating Cash Flow to Sales Ratio
 -78.21 -111.40 -1.56 -1.55 -2.63
Free Cash Flow Yield
-22.28%-21.70%-63.97%-23.33%-42.57%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -3.93 -3.24 -2.34 -3.90 -2.69
Price-to-Sales (P/S) Ratio
 351.60 513.72 2.45 6.65 6.25
Price-to-Book (P/B) Ratio
 5.97 4.61 0.79 7.68 6.13
Price-to-Free Cash Flow (P/FCF) Ratio
 -4.49 -4.61 -1.56 -4.29 -2.35
Price-to-Operating Cash Flow Ratio
 -4.50 -4.61 -1.57 -4.29 -2.37
Price-to-Earnings Growth (PEG) Ratio
 0.18 0.16 0.07 0.45 -0.01
Price-to-Fair Value
 5.97 4.61 0.79 7.68 6.13
Enterprise Value Multiple
 -4.10 -3.09 0.31 -2.02 -1.34
Enterprise Value
 289.22M 276.05M -15.14M 100.43M 80.92M
EV to EBITDA
 -4.10 -3.09 0.31 -2.02 -1.34
EV to Sales
 345.01 493.83 -0.35 3.96 3.74
EV to Free Cash Flow
 -4.40 -4.43 0.22 -2.55 -1.41
EV to Operating Cash Flow
 -4.41 -4.43 0.22 -2.55 -1.42
Tangible Book Value Per Share
 0.82 1.09 8.06 0.94 1.28
Shareholders’ Equity Per Share
 1.05 1.32 8.69 1.78 2.06
Tax and Other Ratios
Effective Tax Rate
 >-0.01 >-0.01 -0.02 0.14 -0.01
Revenue Per Share
 0.02 0.01 2.81 2.05 2.02
Net Income Per Share
 -1.59 -1.88 -2.94 -3.50 -4.69
Tax Burden
 1.00 1.00 1.02 0.86 1.01
Interest Burden
 1.06 0.99 0.90 1.00 0.81
Research & Development to Revenue
 65.95 121.20 1.57 1.73 2.01
SG&A to Revenue
 25.87 39.97 0.62 0.81 1.19
Stock-Based Compensation to Revenue
 17.11 14.44 0.30 0.51 0.59
Income Quality
 0.45 0.70 1.87 0.78 1.13
Currency in GBP